派格生物上市冲动与骨感现实

新浪财经
Jun 09

5月27日,慢性病创新疗法研发公司派格生物在港交所上市。在火热的2型糖尿病(T2DM)及减肥赛道,派格生物是一级市场的明星项目。招股书显示,在IPO之前,派格生物于2008-2023年先后获得9轮融资,投资方包括元生创投、泰格医药、盈科资本、前海、君联资本等一众知名机构与企业。此前,派格生物曾向科创板提交上市申请,后因产品研发战略及全球业务拓展而转战港交所。如今,作为一家尚无产品产生商业化收入的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10